Boehringer and Eli Lilly meet primary endpoints in heart failure treatment studies

In a new phase III trial, Boehringer Ingelheim and Eli Lilly have received positive results with the diabetes drug Jardiance for treating chronic heart failure.
Photo: Boehringer Ingelheim/ PR
Photo: Boehringer Ingelheim/ PR
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT

Boehringer Ingelheim and Eli Lilly have received breakthrough results in their Empreror-Preserved phase III study of type 2 diabetes drug Jardiance. It is the first succesful treatment for chronic heart failure, or a weak pulse with preserved ejection fraction.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading